Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 19, 2019 - Issue 2
Submit an article Journal homepage
3,693
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Approaching drug-induced parkinsonism from a neurohospitalist perspective

Jason MargoleskyDepartment of Neurology, University of Miami Miller School of Medicine, Miami, Fl, USACorrespondence[email protected]
View further author information
Pages 93-95 | Received 17 Nov 2018, Accepted 10 Jan 2019, Published online: 16 Jan 2019

References

  • Lee PH, Yeo SH, Yong SW, et al. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2007;78(11):1250–1252.
  • Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779–787.
  • Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2008;23:401–404.
  • Shuaib UA, Rajput AH, Robinson CA, et al. Neuroleptic-induced Parkinsonism: clinicopathological study. Mov Disord. 2016;31:360–365.
  • Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–2231.
  • Blanchet PJ, Kivenko V. Drug-induced parkinsonism: diagnosis and management. J Parkinsonism Restless Legs Syndr. 2016;6:83–91.
  • Kim JS, Youn J, Shin H, et al. Nonmotor symptoms in drug-induced parkinsonism and drug-naïve parkinson disease. Can J Neuro Sci. 2013;40:36–41.
  • Morley JF, Pawlowski SM, Kesari A, et al. Motor and non-motor features of Parkinson’s disease that predict persistent drug-induced parkinsonism. Parkinsonism Relat Disord. 2014;20(7):738–742.
  • Morley JF, Cheng G, Dubroff JG, et al. Olfactory impairment predicts underlying dopaminergic deficit in presumed drug-induced parkinsonism. Mov Disord Clin Pract. 2016;4:603–606.
  • Howel MJ. Parasomnias: an updated review. Neurotherapeutics. 2012;9:753–775.
  • Ravn AH, Thyseen JP, Egeberg A. Skin disorders in Parkinson’s disease: potential biomarkers and risk factors. Clin Cosmet Invetig Dermatol. 2017;10:87–92.
  • Fereshtehnejad SM, Zeighami Y, Dagher A, et al. Clinical criteria for subtyping Parkinson’s disease: biomarker and longitudinal progression. Brain. 2017;140:1959–1976.
  • Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci. 1990;2:64–66.
  • Alvarez MVG, Evidente VGH. Understanding drug-induced parkinsonism separating pearls from oy-sters. Neurology. 2008;70:e32–e34.
  • Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.
  • Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15–21.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.